276 related articles for article (PubMed ID: 37998368)
1. Potential Crosstalk between the PACAP/VIP Neuropeptide System and Endoplasmic Reticulum Stress-Relevance to Multiple Sclerosis Pathophysiology.
Withana M; Castorina A
Cells; 2023 Nov; 12(22):. PubMed ID: 37998368
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Pro-Phagocytic and Anti-Inflammatory Functions of PACAP and VIP in Microglia: Implications for Multiple Sclerosis.
Jansen MI; Thomas Broome S; Castorina A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563181
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.
Harmar AJ; Fahrenkrug J; Gozes I; Laburthe M; May V; Pisegna JR; Vaudry D; Vaudry H; Waschek JA; Said SI
Br J Pharmacol; 2012 May; 166(1):4-17. PubMed ID: 22289055
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptides shaping the central nervous system development: Spatiotemporal actions of VIP and PACAP through complementary signaling pathways.
Maduna T; Lelievre V
J Neurosci Res; 2016 Dec; 94(12):1472-1487. PubMed ID: 27717098
[TBL] [Abstract][Full Text] [Related]
6. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
7. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
[TBL] [Abstract][Full Text] [Related]
9. VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair.
Waschek JA
Br J Pharmacol; 2013 Jun; 169(3):512-23. PubMed ID: 23517078
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
11. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis.
Baranowska-Bik A; Kochanowski J; Uchman D; Wolinska-Witort E; Kalisz M; Martynska L; Baranowska B; Bik W
J Neuroimmunol; 2013 Oct; 263(1-2):159-61. PubMed ID: 24041830
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
14. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
15. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
[TBL] [Abstract][Full Text] [Related]
16. Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats.
Läuffer JM; Modlin IM; Hinoue T; Kidd M; Zhang T; Schmid SW; Tang LH
Gastroenterology; 1999 Mar; 116(3):623-35. PubMed ID: 10029621
[TBL] [Abstract][Full Text] [Related]
17. Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor.
Tachibana T; Saito ES; Takahashi H; Saito S; Tomonaga S; Boswell T; Furuse M
Regul Pept; 2004 Aug; 120(1-3):99-105. PubMed ID: 15177926
[TBL] [Abstract][Full Text] [Related]
18. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
19. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.
Dickinson T; Fleetwood-Walker SM; Mitchell R; Lutz EM
Neuropeptides; 1997 Apr; 31(2):175-85. PubMed ID: 9179871
[TBL] [Abstract][Full Text] [Related]
20. Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides.
Jansen MI; Broome ST; Castorina A
J Integr Neurosci; 2022 Jan; 21(1):33. PubMed ID: 35164469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
